Business
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
SAN DIEGO, August 05, 2025--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced the dosing of the first patient in its TRACTr collaboration with Merck, known as MSD outside of the United States and Canada
About this update from Janux Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":221,"url":"https://media.zenfs.com/en/business-wire.com/05777e55837fcc2d43da69d11b37f1ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h186Cuiu.2NBrUTxa6hQOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/05777e55837fcc2d43da69d11b37f1ec","width":480,"height":221}},"lazy":false},{"type":"text","content":"First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux","length":103,"tagName":"p"},{"type":"text","content":"SAN DIEGO, August 05, 2025--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced the dosing of the first patient in its TRACTr collaboration with Merck, known as MSD outside of the United States and Canada. Under the terms of the collaboration that was entered in December 2020, Janux is eligible to receive development and commercial milestone payments and royalties.","length":680,"tagName":"p"},{"type":"text","content":""This milestone underscores the strength of our approach to generating value through both internal innovation and strategic partnerships, and it reflects the growing promise of our TRACTr pipeline—precision engineered to selectively modulate T cells to fight cancer," said David Campbell, Ph.D., President and CEO of Janux.","length":333,"tagName":"p"},{"type":"text","content":""We’re thrilled to mark this pivotal achievement with the first clinical program emerging from our collaboration with Merck. This event displays strong collaboration with our partner and the ability to advance novel therapeutics derived from our underlying platforms from discovery into clinical trials," said Janeen Doyle, Chief Corporate and Business Development Officer of Janux.","length":392,"tagName":"p"},{"type":"text","content":"Janux’s TRACTr, TRACIr and ARM Pipeline","length":39,"tagName":"p"},{"type":"text","content":"Janux’s first clinical candidate, JANX...